Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Gains from Investment Securities: 2020-2025

Historic Gains from Investment Securities for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $478,000.

  • Xeris Biopharma Holdings' Gains from Investment Securities rose 475.90% to $478,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year decrease of 58.05%. This contributed to the annual value of $3.7 million for FY2024, which is 81.37% down from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Gains from Investment Securities stood at $478,000 for Q3 2025, which was down 44.42% from $860,000 recorded in Q2 2025.
  • Xeris Biopharma Holdings' Gains from Investment Securities' 5-year high stood at $20.0 million during Q2 2023, with a 5-year trough of -$81,000 in Q3 2021.
  • Moreover, its 3-year median value for Gains from Investment Securities was $861,500 (2023), whereas its average is $5.3 million.
  • In the last 5 years, Xeris Biopharma Holdings' Gains from Investment Securities crashed by 150.62% in 2021 and then surged by 90,771.43% in 2023.
  • Xeris Biopharma Holdings' Gains from Investment Securities (Quarterly) stood at $169,000 in 2021, then crashed by 87.57% to $21,000 in 2022, then soared by 90,771.43% to $19.1 million in 2023, then slumped by 99.13% to $166,000 in 2024, then surged by 475.90% to $478,000 in 2025.
  • Its last three reported values are $478,000 in Q3 2025, $860,000 for Q2 2025, and $8.0 million during Q1 2025.